Vicebio Acquired by Sanofi for $1.6 Billion
Deal News | Jul 22, 2025 | PR Newswire Cision Vicebio
Sanofi, a leading biopharmaceutical company, has reached an agreement to acquire Vicebio, a biotech firm pioneering next-generation vaccines targeting respiratory pathogens, for a total of $1.6 billion. This transaction will allow Sanofi access to Vicebio’s proprietary Molecular Clamp technology, which stabilizes viral proteins to enhance the immune response and is applicable to a range of viruses, including RSV, hMPV, and potentially, coronaviruses. The financial terms include an upfront payment of $1.15 billion and additional milestone payments up to $450 million. Vicebio's lead asset, VXB-241, a bivalent vaccine targeting RSV and hMPV, is undergoing exploratory Phase 1 trials. This strategic acquisition amplifies Sanofi's vaccine portfolio while marking a significant milestone for Vicebio, created by Medicxi. The collaboration promises to accelerate clinical development, potentially transforming global healthcare by expanding protection against life-threatening respiratory infections.
Sectors
- Biotechnology
- Pharmaceutical
- Healthcare Investment
Geography
- United Kingdom – Vicebio is reported in the news to be based in London, UK, where the announcement was made.
- France – Sanofi, the acquiring company, is a multinational pharmaceutical company headquartered in Paris, France.
- Australia – The Molecular Clamp technology was developed at the University of Queensland, Australia, indicating significant geographical relevance.
Industry
- Biotechnology – The article revolves around Vicebio, a company focused on developing innovative vaccines using advanced biotechnology such as Molecular Clamp technology.
- Pharmaceutical – Sanofi, a key participant in the transaction, operates within the pharmaceutical sector, developing and marketing vaccines and medications.
- Healthcare Investment – The acquisition involves significant investment into biotech innovations, highlighted by investments from Medicxi, TCGX, and other financial partners.
Financials
- US$1.6 billion – The total acquisition price Sanofi has agreed to pay for Vicebio.
- US$1.15 billion – The upfront payment included in the acquisition agreement.
- US$450 million – Potential milestone payments contingent on developmental and regulatory achievements.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Vicebio Ltd | Target | Company | A pioneering biotech company focused on developing next-generation vaccines for respiratory diseases using proprietary technology. |
| Sanofi | Acquirer | Company | A major pharmaceutical company that develops vaccines and medicines globally, acquiring Vicebio to enhance its vaccine portfolio. |
| Medicxi | Other | Company | Healthcare-focused investment firm, founding investor in Vicebio, aimed at advancing drug development companies. |
| University of Queensland | Other | Company | Originated the Molecular Clamp technology through scientific research, playing a crucial role in Vicebio's technological assets. |
| Goodwin Procter | Legal Advisor | Company | Acted as legal counsel to Vicebio during the acquisition process. |